Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02711956 · ClinicalTrials.gov registry record · Phase 1
A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Zenith Epigenetics.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 8
- Study locations
NCT02711956 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer that has completed, run by Zenith Epigenetics. The registered enrollment target is 75 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (62% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT02711956, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, has completed, sponsored by Zenith Epigenetics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is an open label, non-randomized, Phase 1b/2a, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.
Conditions Studied
Interventions
- DRUG Enzalutamide
- DRUG ZEN003694
Study Locations (8)
California
- University of California Los Angeles Medical Center - Los Angeles
- University of California San Francisco Medical Center - San Francisco
Michigan
- Karmanos Cancer Institute - Detroit
- Karmanos Cancer Institute - Farmington Hills
New York
- Memorial Sloan Kettering Cancer Center - New York
- Weill Cornell Medicine - New York Presbyterian - New York
Oregon
- Oregon Health & Science University - Portland
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2016-12 |
| Est. Completion | 2019-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02711956
The ClinicalTrials.gov registry entry for NCT02711956 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (62% lower). The listed sponsor is Zenith Epigenetics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Enzalutamide is the first listed.
NCT02711956 reports 8 study locations spanning 5 distinct geographic areas - top geographies include California, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT02711956 about?
NCT02711956 is a clinical study titled "A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer". This is an open label, non-randomized, Phase 1b/2a, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.
What is the current status of trial NCT02711956?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2016-12. Estimated completion is 2019-11.
What conditions does trial NCT02711956 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.
What interventions are being tested in trial NCT02711956?
The interventions under investigation include: Enzalutamide (DRUG), ZEN003694 (DRUG).
Who is sponsoring clinical trial NCT02711956?
This trial is sponsored by Zenith Epigenetics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02711956 being conducted?
This trial has 8 study locations across California, Michigan, New York, Oregon, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
RECRUITING · Phase 1
-
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.